lncRNA JPX Promotes Tumor Progression by Interacting with and Destabilizing YTHDF2 in Cutaneous Melanoma

D Luo, H Tang, L Tan, L Zhang, L Wang, Q Cheng… - Molecular Cancer …, 2024 - AACR
Aberrant long noncoding RNAs just proximal to Xist (lncRNA JPX) expression levels have
been detected in multiple tumors. However, whether JPX is involved in melanoma …

[HTML][HTML] The role of RNA modification in the generation of acquired drug resistance in glioma

Y Yan, W Wei, S Long, S Ye, B Yang, J Jiang… - Frontiers in …, 2022 - frontiersin.org
Glioma is the most common malignant tumor in the central nervous system. The clinical
treatment strategy is mainly surgery combined with concurrent temozolomide chemotherapy …

[HTML][HTML] Insights into the role of RNA m6A modification in the metabolic process and related diseases

H Hu, Z Li, X Xie, Q Liao, Y Hu, C Gong, N Gao… - Genes & …, 2024 - Elsevier
According to the latest consensus, many traditional diseases are considered metabolic
diseases, such as cancer, type 2 diabetes, obesity, and cardiovascular disease. Currently …

Emerging role of long non-coding RNA JPX in malignant processes and potential applications in cancers

Y Wang, H Bai, M Jiang, C Zhou, Z Gong - Chinese Medical Journal, 2023 - mednexus.org
Long non-coding RNAs (lncRNAs) reportedly function as important modulators of gene
regulation and malignant processes in the development of human cancers. The lncRNA JPX …

Critical roles and clinical perspectives of RNA methylation in cancer

G Li, Q Yao, P Liu, H Zhang, Y Liu, S Li, Y Shi, Z Li… - MedComm, 2024 - Wiley Online Library
RNA modification, especially RNA methylation, is a critical posttranscriptional process
influencing cellular functions and disease progression, accounting for over 60% of all RNA …

The Critical Role of RNA m6A Methylation in Gliomas: Targeting the Hallmarks of Cancer

Z Xu, J Jiang, S Wang - Cellular and Molecular Neurobiology, 2023 - Springer
Gliomas are the most common central cancer with high aggressive-capacity and poor
prognosis, remaining to be the threat of most patients. With the blood–brain barrier and …

[HTML][HTML] ZFHX3 acts as a tumor suppressor in prostate cancer by targeting FTO-mediated m6A demethylation

Q Hu, J Yin, S Zhao, Y Wang, R Shi, K Yan… - Cell Death …, 2024 - nature.com
Abstract Zinc-finger homeobox 3 (ZFHX3, also known as ATBF1) suppresses prostatic
tumorigenesis. ZFHX3 is frequently found to have numerous deletions in human prostate …

m6A 修饰对于肿瘤在传统化疗和新型靶向治疗耐药中的作用研究进展

郑思晴, 王昊 - 临床输血与检验, 2023 - lcsxyjy.com
近年来, 癌症治疗取得了巨大进步, 显著提高了临床疗效. 然而, 肿瘤耐药一直是影响癌症治疗
效果的关键问题, 其复杂的机制仍然难以捉摸. N6-甲基腺苷(m6A) 修饰作为表观遗传学研究的 …

[PDF][PDF] Overview of the interplay between m6A methylation modification and non-coding RNA and their impact on tumor cells

Z Dou, XT Ma, MN Piao, JP Wang… - Translational Cancer …, 2024 - cdn.amegroups.cn
N6-methyladenosine (m6A) is one of the most common internal modifications in eukaryotic
RNA. The presence of m6A on transcripts can affect a series of fundamental cellular …

Translational control of C/EBPβ isoform expression: a focus on regulation and function in breast cancer

H Zuidhof - 2022 - research.rug.nl
The widely expressed C/EBPβ transcription factor regulates various cellular processes such
as differentiation, proliferation, migration, senescence and apoptosis to maintain tissue …